Stoke therapeutics stock.

Nov 29, 2023 · Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting. BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit... Find the latest Gain Therapeutics, Inc. (GANX) stock quote, history, news and other vital information to help you with your stock trading and investing.34.02%. Get the latest Stoke Therapeutics Inc (STOK) real-time quote, historical performance, charts, and other financial information to help you make more informed …According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI is also known a narrow therapeutic index or critical dose d...

Stoke’s initial applications for this technology are diseases in which one copy of a gene functions normally and the other is mutated, also called haploinsufficiencies. However, our research has shown that TANGO can increase full-length, fully functional protein expression from a variety of healthy genes. These findings support our belief ...BEDFORD, Mass., December 01, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein ...Stoke Therapeutics, Inc. Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units . From time to time, we may offer up to $400,000,000 ...

Stoke Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.67. See the top stocks recommended by analysts >> The company has a one-year high of $26.60 and a ...

See the latest Stoke Therapeutics Inc stock price (STOK:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Website. 2014. 117. Ed Kaye. https://www.stoketherapeutics.com. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense ...About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense ...Investors & News Stock Information Stock Information Stock Quote Change Volume Today's Open Previous Close Today's High Today's Low 52 Week High 52 …

Stock Information Stock Quote & Chart ... Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on... 09.18.23. Read more. Tango Therapeutics 201 Brookline Ave, Suite 901 Boston, MA 02215 Tel: +1-857-320-4900.

Our Pipeline. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. We are also pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.

Stoke Therapeutics, Inc. Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units . From time to time, we may offer up to $400,000,000 aggregate dollar amount of shares of our common stock or preferred stock, debt securities, warrants to purchase our common stock, preferred stock or debt securities, subscription ...Shares of Iovance Biotherapeutic s ( IOVA 1.98%) were jumping 10.9% higher as of 11:49 a.m. ET on Monday. The nice gain came after Goldman Sachs …As of November 7, 2023, Stoke Therapeutics has amassed a substantial sum of $214.7 million in cash, cash equivalents, and marketable securities. This impressive financial reserve is expected to provide ample support for the company’s ongoing operations until the conclusion of 2025. ... The stock opened at $4.40, slightly higher than the ...Stoke Therapeutics Inc stock price live 3.88, this page displays NASDAQ STOK stock exchange data. View the STOK premarket stock price ahead of the market session or assess the after hours quote. Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business. Find the latest Altamira Therapeutics Ltd. (CYTO) stock quote, history, news and other vital information to help you with ...

Name. Chg %. Market Cap. Jazz Pharmaceuticals PLC. 2.92%. $7.45B. STOK | Complete Stoke Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a...The latest price target for . Stoke Therapeutics (NASDAQ: STOK) was reported by Needham on November 7, 2023.The analyst firm set a price target for $14.00 expecting STOK to rise to within 12 ...Epilepsy & Behavior. November 1, 2022. READ FULL ARTICLE ; Science Translational Medicine. August 26, 2020. Read Full Article ; Nature Communications. July 9, ...Wedbush Lowers Stoke Therapeutics' Price Target to $13 From $18, Shifts STK-001 Launch Timing; Retains Outperform Rating. Aug. 08. MT. Stoke Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023. Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compares to loss of $0.66 per share a year ago.Overview News Stoke Therapeutics Inc. No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-2.54 Market Cap $180.72 M Shares …

10 Jan 2022 ... Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating ...

Company Description. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.Analysts who have issued ratings on the stock over the past year have set an average 1-year target price of $23.50. In other news, insider Barry Ticho sold 15,000 shares of Stoke Therapeutics’ stock on July 3rd at an average price of $10.60 per share. The total value of this transaction amounted to $159,000.Stoke Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.67. See the top stocks recommended by analysts >> The company has a one-year high of $26.60 and a ...Find the latest TG Therapeutics, Inc. (TGTX) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest TransCode Therapeutics, Inc. (RNAZ) stock quote, history, news and other vital information to help you with your stock trading and investing.Aug 16, 2023 · Is Stoke Therapeutics stock a buy? Stoke is a rare opportunity to invest in a cutting-edge biotech company that could revolutionize the treatment of genetic diseases. With a limited yet high-value ... Dec 1, 2023 · Stock analysis for Stoke Therapeutics Inc (STOK:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Thanksgiving is a time of gratitude, family, and gathering around a bountiful meal. While it’s often seen as a holiday for children, adults can also find joy and relaxation during this festive season. One activity that has gained popularity...Stoke Therapeutics Stock Price Chart Technical Analysis: Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and STOK is experiencing selling pressure, which indicates risk of future bearish movement.

Find the latest Moderna, Inc. (MRNA) stock quote, history, news and other vital information to help you with your stock trading and investing.

Discover historical prices for STOK stock on Yahoo Finance. View daily, weekly or monthly format back to when Stoke Therapeutics, Inc. stock was issued.

Nov 20, 2023 · Website. 2014. 117. Ed Kaye. https://www.stoketherapeutics.com. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense ... Find the latest analyst research for Stoke Therapeutics, Inc. Common Stock (STOK) at Nasdaq.com.Stock Information · Analyst Coverage · Governance · Contact Us · Site Logo. Search. Contact Us · LinkedIn · Twitter · About Stoke · Overview · Leadership ...Stoke Therapeutics Stock Price Chart Technical Analysis: Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and STOK is experiencing buying pressure, which is a positive indicator for future bullish movement.BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 29, 2022-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that seven abstracts related to the Company’s work in Dravet syndrome have been accepted ...Dec 1, 2023 · STOK Earnings Date and Information. Stoke Therapeutics last posted its quarterly earnings data on November 7th, 2023. The reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.10. The business earned $3.31 million during the quarter, compared to analyst estimates of $3.83 million. Stoke Therapeutics ( NASDAQ: STOK) lost ~30% in value on Tuesday after the company announced new data from its Phase 1/2a Studies for the antisense oligonucleotide STK-001 targeted at patients ...The estimated Net Worth of Seth Loring Harrison is at least $16.5 Milión dollars as of 30 November 2022. Seth Harrison owns over 23,131 units of Stoke Therapeutics stock worth over $906,146 and over the last 4 years he sold STOK stock worth over $15,056,711. In addition, he makes $525,048 as Independent Chairman of the …Stoke Therapeutics Inc STOK announced data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome.See the latest Stoke Therapeutics Inc stock price (STOK:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

In other news, insider Barry Ticho sold 15,000 shares of Stoke Therapeutics’ stock on July 3rd at an average price of $10.60 per share. The total value of this transaction amounted to $159,000. Following this sale, Ticho now owns 25,895 shares in the company with a valuation of $274,487. This transaction was disclosed through a …Stoke Therapeutics share price went up by 4.58% last month. The next quarterly earnings date for Stoke Therapeutics is scheduled on May 10, 2023. Stoke Therapeutics's next ex-dividend date is April 23, 2023.(RTTNews) - Stoke Therapeutics, Inc. (STOK) Tuesday reported positive safety and efficacy data from two Phase 1/2a studies of its drug candidate STK-001 for the treatment of Dravet syndrome.Stoke Media & Investor Contacts: Dawn Kalmar Chief Communications Officer [email protected] 781-303-8302 Eric Rojas Vice President, Investor Relations [email protected] 617-312-2754 Source: Stoke Therapeutics, Inc.Instagram:https://instagram. helxmost gainers stockswisconsin energy stockwhy is nvda down today BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 3, 2021-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from five presentations related to the ongoing clinical development of STK-001 ...BEDFORD, Mass., September 20, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein ... mt4 stock brokermjna stock ticker Jul. 25, 2023, 12:51 PM. Stoke Therapeutics Inc (NASDAQ:STOK) shares are trading lower after the company released new safety & efficacy data from STK-001 in the Phase 1/2a Studies (MONARCH ... dow jones interactive chart Nov 28, 2023 · Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The […] Stoke Media & Investor Contacts: Dawn Kalmar Chief Communications Officer [email protected] 781-303-8302 Eric Rojas Vice President, Investor Relations [email protected] 617-312-2754 Source: Stoke Therapeutics, Inc.